TrialHuman vaccines & immunotherapeutics2023

A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age.

Kai Chu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.